An Introduction to Renal Cancer
The treatment landscape for renal cell carcinoma (RCC) has been transformed in recent years. Immune checkpoint inhibitors (ICIs) are becoming the first-line treatment for metastatic disease; and combined administrations of two ICIs or one tyrosine kinase inhibitor plus one ICI have greatly improved survival of clear cell RCC, the most common RCC subtype. Improved understanding of RCC pathology, the microenvironment and the immune system is likely to contribute to the development of new treatment.
Browse the content below where leading experts, discuss the latest data in video interviews and short articles from our conference hub and browse the selection of peer-reviewed articles from our journal portfolio. If you’re looking to learn more about the impact of these developments on patient outcomes, our educational activities are a great resource.
Renal Cancer Content
Immunotherapy-based combinations for advanced/metastatic renal cell carcinoma: What have we learned from ASCO GU 2023?
Watch this touchCONGRESS activity exploring advances in immunotherapy treatments for patients with renal cell carcinoma. Filmed following ASCO GU 2023.
- Evaluate the latest efficacy and safety data for immune checkpoint inhibitor-based combinations in the treatment of advanced or metastatic RCC
- Summarize the latest data on the use of biomarkers to predict response to immune checkpoint inhibitor-based combinations
- Explain how the latest data on the use of immune checkpoint inhibitor-based combinations for the treatment of advanced or metastatic RCC may be implemented in clinical practice
Improving outcomes for patients with advanced RCC: What is the role of emerging combination therapies in the first-line setting?
Watch genitourinary oncology experts discuss how emerging combination therapies in the first-line treatment of advanced RCC can improve patient outcomes.
- Evaluate the rationale for the use of combination therapy in patients with advanced RCC
- Discuss the latest efficacy and safety data for established and emerging combination therapies in first-line advanced RCC
- Apply best practice in the management of adverse events associated with combination therapies for first-line advanced RCC
Managing the treatment of patients with advanced renal cell carcinoma
Leading experts provide an overview of the development of advanced RCC, current treatments and how to manage common associated AEs.
The Role of High-Dose IL-2 in mRCC today
Watch leading experts discuss recent developments in checkpoint inhibitor therapy to treat mRCC,5,6 and the findings from a recent analysis of the PROCLAIMSM registry.
Yann-Alexandre Vano, ESMO 2020 – Nivolumab and Ipilimumab or VEGFR Tyrosine Kinase Inhibitor in Naive Metastatic Kidney Cancer: The BIONIKK Trial
Dr Yann-Alexandre Vano joins touchONCOLOGY to discuss the role of personalization of treatment in kidney cancer, and the major findings from the BIONIKK trial investigating nivolumab and ipilimumab as a first-line therapy for patients with kidney cancer. The late-breaking abstract ‘Results from the phase 2 BIOmarker driven trial with Nivolumab (N) and Ipilimumab or VEGFR […]
Lorenza Rimassa, ESMO 2019 – COSMIC-312 study in hepatocellular carcinoma
We joined Lorenza Rimassa (Humanitas Research Hospital-IRCCS) at ESMO 2019 to discuss the Phase III COSMIC-312 study (NCT03755791) of cabozantinib plus atezolizumab versus sorafenib in patients with advanced hepatocellular carcinoma. Questions 1. What are the limitations of current first-line treatment strategies for advanced hepatocellular carcinoma? (0:05) 2. What is the rationale for combining cabozantinib with […]
Immunotherapy in Renal Cell Carcinoma – Highlights of the ASCO 2019 Genitourinary Cancers Symposium
Despite significant advances in diagnosis and treatment, renal cell carcinoma (RCC) remains one of the most lethal cancers. Worldwide, it is the 6th most commonly diagnosed malignancy in men and the 10th in women, and accounted for 5% and 3% of all cancer diagnoses in 2018.1 Although RCC is curable if treated at an early […]
James Brugarolas, ASCO 2019 – Advances in sarcomatoid RCC
At the ASCO 2019 annual meeting, James Brugarolas discusses sarcomatoid renal cell carcinoma, the current challenges and the advances that are defining a new treatment paradigm. Questions 1. What is sarcomatoid renal cell carcinoma (RCC) and what is its prognosis? (0:04) 2. What are the major treatment challenges in sarcomatoid RCC? (0:54) 3. Why is […]
Hamid Emamekhoo, ASCO 2019 – CheckMate 920 study
At the ASCO 2019 annual meeting, Hamid Emamekhoo discusses the efficacy and safety of the combination of nivolumab plus ipilimumab in patients with symptomatic melanoma brain metastases (CheckMate 204) and how these findings will likely impact the management of the disease. Questions 1. What are the limitations of current treatment options for patients with metastatic […]